Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer.

J. S. Fisherman, M. McCabe, M. Noone, F. P. Ognibene, B. Goldspiel, D. J. Venzon, K. H. Cowan, J. A. O'Shaughnessy

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The objective of this phase I trial was to determine the maximal tolerated dose (MTD) of Taxol and doxorubicin administered as a simultaneous intravenous infusion over 72 hours every 21 days. Granulocyte-colony stimulating factor (G-CSF) 10 micrograms/kg, was administered on days 4-18 of each cycle. The treated population consisted of metastatic breast cancer patients previously untreated with chemotherapy for metastatic disease, who had not received doxorubicin in the adjuvant setting and who had bidimensionally measurable disease. The MTD was determined to be 75 mg/m2 of doxorubicin and 160 mg/m2 of Taxol. The dose-limiting toxicity of the combination was clinical typhlitis in three of three patients. Other significant toxicities included grade 3 diarrhea at the higher dose levels and grade 4 neutropenia in all patients. Eighteen patients were treated on this initial phase I study. The overall response rate was 62%, with 6% complete responses and 56% partial responses. The combination of doxorubicin and Taxol by 72-hour continuous infusion with G-CSF is an active regimen in patients with metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalJournal of the National Cancer Institute. Monographs
Issue number15
StatePublished - 1993

Fingerprint

Granulocyte Colony-Stimulating Factor
Paclitaxel
Doxorubicin
Breast Neoplasms
Maximum Tolerated Dose
Typhlitis
Neutropenia
Intravenous Infusions
Diarrhea
Drug Therapy
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Fisherman, J. S., McCabe, M., Noone, M., Ognibene, F. P., Goldspiel, B., Venzon, D. J., ... O'Shaughnessy, J. A. (1993). Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer. Journal of the National Cancer Institute. Monographs, (15), 189-194.

Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer. / Fisherman, J. S.; McCabe, M.; Noone, M.; Ognibene, F. P.; Goldspiel, B.; Venzon, D. J.; Cowan, K. H.; O'Shaughnessy, J. A.

In: Journal of the National Cancer Institute. Monographs, No. 15, 1993, p. 189-194.

Research output: Contribution to journalArticle

Fisherman, JS, McCabe, M, Noone, M, Ognibene, FP, Goldspiel, B, Venzon, DJ, Cowan, KH & O'Shaughnessy, JA 1993, 'Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer.', Journal of the National Cancer Institute. Monographs, no. 15, pp. 189-194.
Fisherman, J. S. ; McCabe, M. ; Noone, M. ; Ognibene, F. P. ; Goldspiel, B. ; Venzon, D. J. ; Cowan, K. H. ; O'Shaughnessy, J. A. / Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer. In: Journal of the National Cancer Institute. Monographs. 1993 ; No. 15. pp. 189-194.
@article{320e0aa0fdf64960974a25f8aa2e684f,
title = "Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer.",
abstract = "The objective of this phase I trial was to determine the maximal tolerated dose (MTD) of Taxol and doxorubicin administered as a simultaneous intravenous infusion over 72 hours every 21 days. Granulocyte-colony stimulating factor (G-CSF) 10 micrograms/kg, was administered on days 4-18 of each cycle. The treated population consisted of metastatic breast cancer patients previously untreated with chemotherapy for metastatic disease, who had not received doxorubicin in the adjuvant setting and who had bidimensionally measurable disease. The MTD was determined to be 75 mg/m2 of doxorubicin and 160 mg/m2 of Taxol. The dose-limiting toxicity of the combination was clinical typhlitis in three of three patients. Other significant toxicities included grade 3 diarrhea at the higher dose levels and grade 4 neutropenia in all patients. Eighteen patients were treated on this initial phase I study. The overall response rate was 62{\%}, with 6{\%} complete responses and 56{\%} partial responses. The combination of doxorubicin and Taxol by 72-hour continuous infusion with G-CSF is an active regimen in patients with metastatic breast cancer.",
author = "Fisherman, {J. S.} and M. McCabe and M. Noone and Ognibene, {F. P.} and B. Goldspiel and Venzon, {D. J.} and Cowan, {K. H.} and O'Shaughnessy, {J. A.}",
year = "1993",
language = "English (US)",
pages = "189--194",
journal = "NCI Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "15",

}

TY - JOUR

T1 - Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer.

AU - Fisherman, J. S.

AU - McCabe, M.

AU - Noone, M.

AU - Ognibene, F. P.

AU - Goldspiel, B.

AU - Venzon, D. J.

AU - Cowan, K. H.

AU - O'Shaughnessy, J. A.

PY - 1993

Y1 - 1993

N2 - The objective of this phase I trial was to determine the maximal tolerated dose (MTD) of Taxol and doxorubicin administered as a simultaneous intravenous infusion over 72 hours every 21 days. Granulocyte-colony stimulating factor (G-CSF) 10 micrograms/kg, was administered on days 4-18 of each cycle. The treated population consisted of metastatic breast cancer patients previously untreated with chemotherapy for metastatic disease, who had not received doxorubicin in the adjuvant setting and who had bidimensionally measurable disease. The MTD was determined to be 75 mg/m2 of doxorubicin and 160 mg/m2 of Taxol. The dose-limiting toxicity of the combination was clinical typhlitis in three of three patients. Other significant toxicities included grade 3 diarrhea at the higher dose levels and grade 4 neutropenia in all patients. Eighteen patients were treated on this initial phase I study. The overall response rate was 62%, with 6% complete responses and 56% partial responses. The combination of doxorubicin and Taxol by 72-hour continuous infusion with G-CSF is an active regimen in patients with metastatic breast cancer.

AB - The objective of this phase I trial was to determine the maximal tolerated dose (MTD) of Taxol and doxorubicin administered as a simultaneous intravenous infusion over 72 hours every 21 days. Granulocyte-colony stimulating factor (G-CSF) 10 micrograms/kg, was administered on days 4-18 of each cycle. The treated population consisted of metastatic breast cancer patients previously untreated with chemotherapy for metastatic disease, who had not received doxorubicin in the adjuvant setting and who had bidimensionally measurable disease. The MTD was determined to be 75 mg/m2 of doxorubicin and 160 mg/m2 of Taxol. The dose-limiting toxicity of the combination was clinical typhlitis in three of three patients. Other significant toxicities included grade 3 diarrhea at the higher dose levels and grade 4 neutropenia in all patients. Eighteen patients were treated on this initial phase I study. The overall response rate was 62%, with 6% complete responses and 56% partial responses. The combination of doxorubicin and Taxol by 72-hour continuous infusion with G-CSF is an active regimen in patients with metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0027791808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027791808&partnerID=8YFLogxK

M3 - Article

C2 - 7517154

AN - SCOPUS:0027791808

SP - 189

EP - 194

JO - NCI Monographs

JF - NCI Monographs

SN - 1052-6773

IS - 15

ER -